Stage (next event)
Catalyst Info & Data Links
Mechanism of Action
MECHANISM OF ACTION
TD-0903 is a lung-selective nebulized Janus kinase inhibitor (JAKi). TD-0903 has progressed into a Phase 2 clinical development study to assess its utility in preventing the cytokine storm associated with Acute Lung Injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to Acute Respiratory Distress Syndrome (ARDS).
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post